Month: August 2021
Canaccord Presentation August 12, 2021
Wedbush Presentation August 11, 2021
Q2 Half Year Report 2021
ObsEva Announces Second Quarter 2021 Financial Results and Business Update
-Linzagolix (Yselty®) for uterine fibroids: US New Drug Application filing planned in Q3:21; European marketing approval recommendation anticipated in Q4:21-…
ObsEva Announces Two Cornerstone Publications Describing Clinical Trials of Nolasiban for Improving Pregnancy and Live Birth Outcomes Following IVF
– A Combined Analysis of Pregnancy and Live Birth in more than 1800 IVF Patients Across Three Randomized, Placebo-Controlled Clinical…
ObsEva to Present at Upcoming Investor Conferences
GENEVA, Switzerland August 3, 2021 – ObsEva SA (NASDAQ: OBSV; SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies…
The mechanism of action of oxytocin antagonist nolasiban in ART in healthy female volunteers
Piotr Pierzyński; Oliver Pohl; Line Marchand; Shari Mackens; Ulrike Lorch; Jean-Pierre Gotteland; Christophe Blockeel